What the NHS will — and won't — fund for knee cartilage

For most patients in Lincolnshire asking whether cartilage repair is available on the NHS, the honest answer is: sometimes — but within tightly drawn limits.

The sole NHS commissioning route for cell-based knee cartilage repair is NICE Technology Appraisal 477, published in October 2017. TA477 approves Autologous Chondrocyte Implantation (ACI) and its matrix-assisted variant, MACI, making them the only cell therapies the NHS funds for knee cartilage defects. No other cell-based option currently sits within NHS commissioning — including STACI, the newer single-stage approach covered in detail later in this article.

Access is not automatic. TA477 sets a specific eligibility threshold, and patients who do not meet every criterion are not entitled to funded treatment — regardless of how much pain they are in. The full criteria are set out in the next section, but the headline point is that the damage must be focal, the joint must not show significant osteoarthritic change, and the patient must not have undergone previous cartilage repair surgery on the same knee.

For those who do qualify, the geographic reality adds another layer of difficulty. NHS ACI and MACI are performed at a small number of designated tertiary centres — principally the Robert Jones and Agnes Hunt Orthopaedic Hospital (RJAH) in Oswestry, the Royal National Orthopaedic Hospital (RNOH) in Stanmore, and University Hospital Southampton. None of these is in Lincolnshire, meaning patients who meet the criteria face a substantial journey as part of their NHS care.

How MACI works and what it offers over earlier ACI

MACI — Matrix-induced Autologous Chondrocyte Implantation — is the third generation of cell-based cartilage repair, and the version most closely associated with NHS practice under NICE TA477.

The procedure runs in two distinct stages. In stage one, a surgeon performs a short keyhole operation to harvest a small sample of healthy cartilage from a non-weight-bearing zone of the knee. That sample is then sent to a specialist cell-culture laboratory — the RJAH Oscell facility in Oswestry being a key UK example — where the chondrocytes multiply over approximately four to six weeks, expanding at least twentyfold before being seeded onto a flat Type I/III collagen membrane.

Stage two is an open operation. The cell-seeded membrane is shaped to fit the defect, then fixed directly onto the prepared bone bed. Because the scaffold holds the cells in position mechanically, surgeons no longer need to harvest a periosteal flap from elsewhere in the knee — a technical step that first-generation ACI required and that added operative complexity and an additional donor site. This simplification is the primary surgical advantage MACI holds over first-generation ACI, though both remain two-stage pathways of similar overall duration.

The clinical case for MACI in larger defects is supported by the SUMMIT trial, which showed that patients with cartilage injuries of 3 cm² or more had meaningfully better KOOS pain and function scores at both two and five years with MACI than with microfracture.

One firm boundary applies regardless of defect size: MACI is not appropriate when significant osteoarthritic change is already present in the joint. Where cartilage loss has become diffuse rather than focal, cell-based repair is unlikely to succeed, and the eligibility criteria in NICE TA477 reflect that limit explicitly.

The NICE eligibility criteria — who actually qualifies

NICE TA477 sets four clinical gates, all of which must be met before NHS funding can be approved.

Defect size above 2 cm². Smaller focal lesions are typically addressed with microfracture or osteochondral autograft transfer (OATS) first; ACI and MACI are reserved for cases where those options are less likely to succeed or have already been attempted — although the prior-repair rule below complicates that logic.

No significant osteoarthritic change. Cell-based repair targets focal, isolated damage. Where cartilage loss has spread across the joint compartment, the biological environment is unlikely to support graft integration, and NICE guidance excludes these patients from funded treatment. A diagnostic MRI scan is therefore essential to establish how localised the damage is.

No prior cartilage repair surgery on the same knee. This is a first-time-repair-only criterion, and in practice it catches a meaningful proportion of patients who come forward for specialist assessment. Many will have undergone earlier microfracture — often performed arthroscopically for a smaller or acutely symptomatic lesion — which then disqualifies them from NHS-funded ACI or MACI under current guidance, even when the original repair has failed and the defect has enlarged.

Age typically between 16 and 55. The guideline reflects the evidence base rather than setting a hard legal cutoff, so clinical judgement can apply at the margins, but the expectation is a younger, active patient population.

Access also requires a GP referral to one of the designated specialist centres, where volume and quality-assurance standards form part of the commissioning rationale.

STACI — the single-stage alternative and why it is private-only

Removing the laboratory culture phase is the defining feature of STACI — Single-Treatment Autologous Chondrocyte Implantation — and the change that compresses what MACI delivers across two hospital visits and four to six weeks into a single operative session.

The procedure takes place entirely within the theatre. A small sample of healthy cartilage is harvested from a non-weight-bearing area of the knee; an on-site laboratory team then enzymatically frees the chondrocytes without altering their character or viability. Simultaneously, bone marrow drawn from within the same surgical field yields concentrated mesenchymal stem cells (MSCs). The two cell populations are combined and seeded immediately onto a shaped biodegradable collagen scaffold, cut precisely to fit the defect, and implanted in the same sitting. Nothing leaves the theatre; there is no interval between stages.

The scaffold differs structurally from the flat collagen membrane used in MACI. Its three-dimensional architecture supports cell growth across both depth and surface area, which suits larger or geometrically complex defects and, in principle, joints beyond the knee — though for cartilage repair in this context, the knee is the primary indication.

STACI is not covered by NICE TA477. That October 2017 guidance was written specifically around the two-stage, laboratory-culture model of ACI and MACI; a theatre-based single-stage variant sits outside the procedure it defines. Published clinical underpinning includes Taylor & Lee (2019), which characterised STACI as the next generation of autologous chondrocyte implantation, but the supporting evidence base remains considerably smaller than the long-term trial data behind MACI. NICE has not reviewed TA477 since 2017, and the route to NHS commissioning for STACI is currently uncertain.

STACI is therefore available only through the private pathway. Patients who want to avoid a two-stage process, or who do not meet NHS eligibility criteria, may find it worth exploring — with the clear understanding that, while the mechanism is clinically grounded, the evidence is at an earlier stage than for MACI.

The private knee cartilage pathway in Lincolnshire

For patients in Lincolnshire who fall outside NHS eligibility or prefer not to wait, the specialist private resource for knee cartilage repair is the Lincolnshire Knee Clinic at MSK House, Silk Willoughby, Sleaford (NG34 8NY). The clinic operates a one-stop model — consultation, imaging via onsite open MRI with onMRI™ AI-assisted cartilage analysis, and treatment planning in a single visit, with no GP referral required. The lead surgeon holds a Consultant Cartilage Surgeon designation and a Visiting Professorship at the University of Lincoln; cell-based cartilage repair, including STACI, is central to the service. For patients with particularly complex defects, cases can also be managed through the group's London arm at Harley Street.

Broader private orthopaedic knee services are available elsewhere in the county. Lincoln Hospital (Circle Health Group) and Boston West Hospital (Ramsay Health Care) both offer private consultant knee care across a range of knee conditions and procedures. These are appropriate settings for many knee complaints, but specialist cartilage reconstruction — particularly cell-based repair — is a distinct subspecialty; patients with this specific requirement should confirm what procedures are available before booking.

Indicative private costs

Private costs in this sector are estimates rather than fixed tariffs, and MACI or ACI pricing is not published by most private providers in the UK because the procedure is rarely available outside a small number of centres. The figures below are approximate planning guides:

• Initial consultation: £200–£250
• Microfracture: from approximately £4,000
• STACI (all-inclusive): approximately £28,000

Patients should request an itemised written estimate before committing to any procedure, as individual inclusions vary.

Lincolnshire Knee is part of the MSK Doctors group and accepts patients without referral — book an assessment at lincolnshireknee.co.uk.

NHS or private — how to decide which route to pursue

Three questions roughly determine which route makes sense.

Does the patient meet NICE TA477 criteria? A focal defect above 2 cm², no previous cartilage repair surgery on the same knee, minimal osteoarthritic change in the wider joint, and an age typically between 16 and 55 — if all four apply, a GP referral to a designated specialist centre (RJAH Oswestry, RNOH Stanmore, or University Hospital Southampton) is the appropriate first step. The NHS pathway exists for these patients, and for them it is the right one.

Is established osteoarthritis present across the joint? If so, cell-based repair — whether MACI on the NHS or STACI privately — is not appropriate. That boundary applies equally to both routes; the conversation shifts to joint preservation or replacement.

Does timing matter? NHS waiting times for knee surgery commonly run six to twelve months or longer against the 18-week constitutional target. For a patient whose cartilage damage is progressing, or who does not meet NICE criteria at all, the private pathway removes both the eligibility gate and the queue. STACI, available only privately, also removes the two-stage timeline that MACI requires — a relevant factor for patients who cannot commit to two surgical episodes several weeks apart.

For most patients, the practical next step on any of these branches is an assessment that establishes defect size, OA status, and eligibility — because without imaging those questions remain open. Lincolnshire Knee accepts patients without GP referral and can provide that diagnostic starting point, whether the eventual pathway leads to an NHS referral or to private treatment. Appointments can be made at lincolnshireknee.co.uk.